HIV
Cohort Study | Association of HIV infection and incident abdominal aortic aneurysm
31 May, 2023 | 13:55h | UTC
Phase 2 RCT | Single high-dose L-AmB shows comparable efficacy to standard treatment in HIV/AIDS-related histoplasmosis
29 May, 2023 | 10:41h | UTCSee also: Visual Abstract
A humorous peek into HIV research papers: a quick guide
18 May, 2023 | 13:46h | UTCTypes of HIV Papers — A Quick Guide – HIV and Observations
Commentary on Twitter
In his latest HIV and ID Observations post, @PaulSaxMD presents a quick guide to the different types of HIV papers, comic style. https://t.co/RYW6MuubCd (H/T @xkcd) pic.twitter.com/Zlh7PJOh8o
— NEJM Journal Watch (@JWatch) May 16, 2023
RCT | ART intensification shows no benefit in treating HIV-associated neurocognitive impairment
18 May, 2023 | 13:31h | UTC
Cohort Study | Infection-unrelated cancers are increasingly more common than infection-related cancers among individuals with HIV
2 May, 2023 | 13:32h | UTCAge and Cancer Incidence in 5.2 Million People With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study – Clinical Infectious Diseases (free for a limited period)
Commentary: Infection-Unrelated Cancers Predominant Among Older Adults With HIV – Cancer Therapy Advisor
Commentary on Twitter
Age and Cancer Incidence in 5.2 Million People With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study
🆓 Freely Availablehttps://t.co/LMlF30Zkry
— Clinical Infectious Diseases (@CIDJournal) April 30, 2023
Podcast | HIV in primary care
6 Apr, 2023 | 13:13h | UTC#388 HIV in Primary Care with Dr. Jonathan J. “JJ” Nunez MD – The Curbsiders
Cohort Study | Barriers to starting direct-acting antiviral treatment despite access for HIV & hepatitis C patients
6 Apr, 2023 | 13:09h | UTCInvited Commentary: The road to hepatitis C virus elimination – The Lancet Public Health
Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
30 Mar, 2023 | 13:49h | UTC
M-A | Factors associated with post-treatment control of viral load in HIV-infected patients
29 Mar, 2023 | 12:56h | UTC
Updated recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission
15 Mar, 2023 | 15:22h | UTC
RCT | Long-term effects of early antiretroviral therapy initiation in HIV infection highlight the importance of early treatment
1 Mar, 2023 | 14:12h | UTCSummary: The article discusses the long-term results of the Strategic Timing of AntiRetroviral Treatment (START) trial, which aimed to determine the effects of early initiation of antiretroviral therapy (ART) for individuals with HIV and CD4+ counts above 500 cells/mm3 compared to those who deferred treatment until their CD4+ count was below 350 cells/mm3. The trial found that immediate ART initiation reduced the risk of AIDS and serious non-AIDS (SNA) conditions compared to deferred treatment. The study’s long-term results also found that a persistent excess risk of AIDS and SNA conditions remained even after ART was initiated in those who initially deferred treatment. The study highlights the importance of early diagnosis and prompt initiation of ART for individuals with HIV.
Article: Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection – NEJM Evidence
Original Study: Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection – New England Journal of Medicine
M-A | Adverse perinatal outcomes associated with antiretroviral therapy in women living with HIV
27 Feb, 2023 | 12:48h | UTC
Mpox outbreak in advanced HIV cases | Global case series reveals higher mortality and clinical complications
23 Feb, 2023 | 13:44h | UTCSummary: This article discusses a case series investigating monkeypox (mpox) in people with HIV and low CD4 cell counts. The mpox outbreak in 2022 has affected a significant percentage of people living with HIV, and data suggest worse clinical outcomes and higher mortality in those with more advanced HIV. The case series includes data from 382 confirmed mpox cases in people living with HIV from 19 countries. The individuals included were predominantly cisgender men, with a median age of 35. Most individuals were adherent to antiretroviral therapy, and the median CD4 count was 211 cells per mm3. Severe complications were more common in those with lower CD4 cell counts, including necrotizing skin lesions, lung involvement, secondary infections, and sepsis. Approximately 28% of individuals were hospitalized, and 25% of those hospitalized died. All deaths occurred in people with CD4 counts of less than 200 cells per mm3. The study reinforces the importance of HIV and CD4 testing in mpox cases, prioritization of preventive mpox vaccination in people with HIV and a CD4 cell count of less than 200 cells per mm3, and the use of potential mpox antivirals where available. The authors suggest that a severe, disseminated, and necrotizing form of mpox should be considered an AIDS-defining condition in CDC and WHO HIV disease classifications. Clinicians should also be aware that starting antiretroviral therapy in people with advanced HIV and mpox could contribute to deterioration and possible death, possibly as part of an immune reconstitution syndrome.
Article: Mpox in people with advanced HIV infection: a global case series – The Lancet (free registration required)
News Release: Clinicians identify severe form of mpox with high mortality in people with advanced HIV – Queen Mary University of London
Commentaries:
Mpox: Clinicians identify severe form with high mortality in advanced HIV patients – The BMJ
Commentary from the author on Twitter (thread – click for more)
📣 📣 Our global case series on MPOX in people with advanced HIV infection is at #CROI2023 and in @TheLancet today: 382 cases of human MPOX infection in PLWH with CD4 counts <350 cells/mm3 in 19 countries
**We found MPOX is an opportunistic pathogen** /1https://t.co/WodDN4Ujoj pic.twitter.com/IlK7viABmy— Chloe Orkin (@profchloeorkin) February 21, 2023
152-week results of a RCT | Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection
23 Feb, 2023 | 13:16h | UTC
Late diagnosis of HIV: an updated consensus definition
14 Feb, 2023 | 10:49h | UTCLate diagnosis of HIV: An updated consensus definition – HIV Medicine
RCT | Pregnancy and neonatal safety of PrEP for HIV prevention initiated during pregnancy vs. afterwards
9 Feb, 2023 | 13:55h | UTCPregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)
Update guidelines for women with HIV who are virally suppressed incorporate breastfeeding their infants as a viable option
6 Feb, 2023 | 13:40h | UTC
Commentary on Twitter
Updated guidelines now incorporate breastfeeding options for PWH with suppressed VL on ART. https://t.co/JPR1K8zzv6
— Carlos del Rio (@CarlosdelRio7) February 3, 2023
M-A | Revisiting the evidence base for modern-day practice of the treatment of toxoplasmic encephalitis
27 Jan, 2023 | 12:14h | UTC
Phase 2 RCT | Lenacapavir every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV
27 Jan, 2023 | 12:00h | UTCLenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial – The Lancet HIV (link to abstract – $ for full-text)
BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.
15 Dec, 2022 | 13:52h | UTCBHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 – HIV Medicine
Consensus Recommendations | Antiretroviral drugs for treatment and prevention of HIV infection in adults.
2 Dec, 2022 | 14:45h | UTCAntiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults2022 Recommendations of the International Antiviral Society–USA Panel – JAMA (free for a limited period)
Invited Commentary: Ending the HIV Epidemic: We Have the Tools, Do We Have the Will? – JAMA (free for a limited period)
Author Interview: Advances in Treatment and Prevention of HIV – JAMA
How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?
29 Sep, 2022 | 13:26h | UTC
Commentary on Twitter
How applicable is the single-dose liposomal amphotericin B (AMBITION regimen) for HIV-associated cryptococcal meningitis to high-income settings?
Very, argue leaders of the @ambitioncm2020 trial in @CIDJournal https://t.co/eUlWG0t1Xv pic.twitter.com/8JGBU1oWeO
— Ilan Schwartz MD PhD (@GermHunterMD) September 27, 2022
Under a https://creativecommons.org/licenses/by/4.0/ license
Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.
16 Sep, 2022 | 12:50h | UTCGlobal, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019 – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary on Twitter
New analysis of #GBD data reports the global incidence of #HIV and other #STIs in adolescents and young adults https://t.co/hSjgHMGg4R pic.twitter.com/JBd7Goa9Sa
— The Lancet Child & Adolescent Health (@LancetChildAdol) September 13, 2022
Systematic Review | Association of HIV infection with cardiovascular pathology based on advanced cardiovascular imaging.
15 Sep, 2022 | 13:02h | UTCAssociation of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review – JAMA (free for a limited period)
Editorial: HIV, Subclinical Cardiovascular Disease, and Clinical Progression: Insights From Immunologic Heterogeneity – JAMA (free for a limited period)
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomized ODYSSEY trial.
8 Sep, 2022 | 14:33h | UTC
Commentary on Twitter
New: Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial by Pauline Amuge @bayloruganda and colleagues @MRCCTU https://t.co/mc1jWSXMU2 #openaccess pic.twitter.com/A10LgZcwjF
— The Lancet HIV (@TheLancetHIV) September 1, 2022